Actually, it’s not so hard to create a digital health project. It’s not so hard to build software. It’s not so hard to get it online. But getting it to scale, creating an ecosystem, getting it adopted – those are the vital steps that confound us all.
This whitepaper addresses the problem every pharmaceutical company faces: adopting different DNA. The need to become expert in a different type of development, quite alien from the work of progressing chemical or biological therapies. It requires a new type of organisation, a new way of working and the ability to accept help.
We propose that help takes the form of a platform. A software platform designed to ensure you thrive in this ecosystem and have the highest chance of success. This paper explores the possibilities that a platform approach offers and the types available, evaluating their different features, qualities, pros and cons.
Paul Simms Chief Executive Impatient Health Read more
Caoimhe Vallely-Gilroy Former Global Head Of Digital Health & Therapeutics Merck KGaA
John Mulcahy Vice President Of Product Management S3 Connected Health
Francesca Wuttke CEO And Founder Nen Health
Leslie Anne Fendt Global Integrated Solutions Product Leader – Digital Health Roche
Jim O’Donoghue President S3 Connected Health
Wolfgang Schleifer Head of Digital Delivery Novartis
Shwen Gwee Former Vice President and Head Of Global Digital Strategy BMS
Irina Osovskaya Global Digital Strategy Director AstraZeneca
Adam Higgins Head Of Digital Strategy, EMEA Janssen
This paper was born from interviews with several of our industry’s most seasoned digital health players. It became clear that a better approach was needed for the development and distribution of digital health within large companies, at scale. And with increasing pressure on digital pipelines, we can no longer afford to play around: we need to capitalise on what we’ve learned about bringing projects into the real world, with a platform approach.
Download your copy of the whitepaper